Skip to content

    Orchid Pharma Limited

    ORCHPHARMAMixed
    Healthcare·26 May 2025
    Management Summary

    Orchid Pharma reported a 9% YoY sales growth to Rs. 237 crores and an EBITDA of Rs. 40 crores for Q4 FY25. Full-year FY25 sales grew 13% to Rs. 922 crores with an EBITDA of Rs. 156 crores. Key projects like 7-ACA faced delays, pushing commercialization to March 2027, while Enmetazobactam showed strong traction in India. The company anticipates a muted FY26 due to pricing pressures and CAPEX, but expects the merged Dhanuka Laboratories entity to provide a stronger platform with over Rs. 1,500 crore revenue.

    Highlights

    8
    • Q4 FY25 sales reached Rs. 237 crores, marking a 9% increase year-over-year.

    • EBITDA for Q4 FY25 stood at Rs. 40 crores.

    • Full-year FY25 sales grew 13% to Rs. 922 crores, up from Rs. 819 crores in FY24.

    • FY25 EBITDA was Rs. 156 crores, compared to Rs. 140 crores in FY24.

    • The AMS division incurred an operating drag of Rs. 9 crores in FY25 and is expected to remain EBITDA negative for approximately two more years.

    • The 7-ACA project's mechanical completion is delayed by 6 months to December 2026, with the first commercial product targeted for March 2027.

    • Enmetazobactam demonstrated strong early traction in India, achieving 10,000 patient treatments in half a year, which was the full-year estimate.

    • The merger with Dhanuka Laboratories has been cleared, projecting a combined entity revenue exceeding Rs. 1,500 crore and EBITDA of roughly Rs. 175 crore for FY26.

    Concerns

    3
    • 7-ACA Project Execution Delay

    • Enmetazobactam US Commercialization Impact from Allecra Insolvency

    • Continued Pricing Pressure and Muted FY26 Outlook

    What Changed2

    vs Q1 FY26

    Guidance items7 → 12 (+5)Risks discussed3 → 7 (+4)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹237 Cr+9%YoY
    2. 02EBITDA₹40 Cr
    3. 03Full Year Revenue₹922 Cr+13%YoY
    4. 04Full Year EBITDA₹156 Cr
    5. 05Full Year Volume Growth19%

    Segment breakdown

    Dhanuka Laboratories (FY25)
    ₹506 Cr Sales₹48 Cr EBITDA
    Antimicrobial Solution (AMS) Division (FY25)
    ₹9 Cr EBITDA Drag
    List

    Guidance & targets

    12
    CategoryTargetPriority
    Profitability
    AMS Division Profitability
    profitable
    Medium
    Profitability
    Merged Entity EBITDA
    roughly Rs. 175 crore
    Medium
    Capacity
    7-ACA Project Mechanical Completion
    December 2026
    Medium
    Capacity
    7ACA Scale-up
    1,000 liters
    High
    Product Launch
    7-ACA First Commercial Product
    March 2027
    Medium
    Product Launch
    Cefiderocol First Validation Batches
    last quarter of 2026
    High
    Product Launch
    Cefiderocol Commercial Launch
    second quarter of calendar year 2027
    High
    Other
    Dhanuka Merger Legal Process Completion
    within this Financial Year
    High
    Revenue
    Merged Entity Revenue
    in excess of Rs. 1,500 crore
    Medium
    Margin
    Margin Aspiration
    mid-teen
    High
    Product Pipeline
    ANDA Filings
    2 to 3 differentiated cephalosporin ANDAs
    High
    Volume
    Volume Growth
    mid-teens
    Medium

    Risks & concerns

    9
    RiskSeverity

    7-ACA Project Execution Delay

    Mechanical completion of the 7-ACA project is delayed by 6 months to December 2026 due to site challenges.Management acknowledged

    high

    Enmetazobactam US Commercialization Impact from Allecra Insolvency

    Electrotherapeutics' insolvency filing in Germany clouds near-term commercialization of Enmetazobactam in the US and other international markets.Management acknowledged

    high

    AMS Division Operating Drag

    The Antimicrobial Solution (AMS) division was EBITDA negative by Rs. 9 crores in FY25 and is expected to remain a drag for roughly two more years.Management acknowledged

    medium

    Continued Pricing Pressure and Muted FY26 Outlook

    The company expects a muted FY26 due to ongoing pressure on demand and pricing, impacting overall numbers.Management acknowledged

    high

    Surge in Receivables and Inventory

    A sudden surge in receivables and inventories tied up cash, attributed to sales in the last two months and higher inventory due to pricing pressure.Analyst acknowledged

    medium

    Penicillin Price Compression

    Reduction in Pen-G prices is leading to price reduction, impacting products like Cefepime, with uncertainty on competitor reactions.Management acknowledged

    medium

    Dependency on Customers for US Market Entry

    Historically, the company was exclusively dependent on a few customers for US market entry, but is now developing its own ANDAs and working with CMOs to mitigate this.Analyst acknowledged

    medium

    Areas of Evasion(2)

    • Allecra legal standing and options post-insolvency
    • Specific margin profile for Enmetazobactam in India

    Q&A highlights

    3

    “Unfortunately, this is a public call, so I will not be able to share with you the options. Once we have them legally, we have to figure out our strategy. So it's a little too early because the announcement has just come.”

    Management was unable to provide clarity on the financial implications of Allecra's insolvency, including unreceived royalties and their standing as a creditor, indicating significant uncertainty.

    asked by Rupesh Tatiya

    3 min read7 chapters

    Detailed Narrative

    01

    Q4 FY25 Performance and Full Year Overview

    Orchid Pharma reported Q4 FY25 sales of Rs. 237 crores, a 9% increase year-over-year, with an EBITDA of Rs. 40 crores. For the full fiscal year 2025, sales grew 13% to Rs. 922 crores, up from Rs. 819 crores in FY24, and EBITDA reached Rs. 156 crores, compared to Rs. 140 crores in the previous year. The company also achieved an 18-20% volume growth for FY25, despite absorbing a Rs. 6 crore one-time📎 expense for GMP inspections in Q3.

    02

    Antimicrobial Solutions (AMS) Division Update

    The AMS division, launched last year to cater to hospital sales, closed FY25 with a team of 70 members and engagements with over 500 physicians. However, it incurred an EBITDA negative drag of Rs. 9 crores for the year. Management anticipates the division will remain a drag for roughly two more years before achieving profitability, as it is still in its build-out phase and developing its sales and marketing model.

    03

    Key Project Timelines and Challenges

    The 7-ACA project faces a 6-month delay, with mechanical completion now targeted for December 2026 and the first commercial product for March 2027. For Enmetazobactam, while India shows strong traction with 10,000 patients treated in half a year (matching the full-year estimate), US commercialization is clouded by Allecra's insolvency filing. The Cefiderocol project remains on schedule, with first validation batches expected in Q4 2026 and commercial launch in Q2 2027, pending regulatory approval in India.

    04

    Dhanuka Laboratories Merger and Combined Entity Outlook

    The National Capital Law Tribunal (NCLT) has cleared the merger of Dhanuka Laboratories into Orchid Pharma, with the legal process expected to conclude within FY26. The combined entity is projected to generate revenue in excess of Rs. 1,500 crore and an EBITDA of roughly Rs. 175 crore for FY26. Dhanuka Laboratories contributed Rs. 506 crores in sales and Rs. 48 crores in EBITDA for FY25, providing a stronger platform for future growth.

    05

    FY26 Outlook and Strategic Focus

    Orchid Pharma anticipates a muted FY26 due to continued pricing pressure and the ramp-up of CAPEX for the 7-ACA facility. Despite this, the company's mid-teen margin aspiration remains intact, supported by volume growth, mixed optimization, and disciplined cost control. The company also plans to file 2 to 3 differentiated cephalosporin ANDAs for the US market within the next 12 to 18 months, aiming to stay at the forefront of complex anti-infectives.

    06

    Raw Material Pricing and Inventory Management

    The company experienced a sudden surge in receivables and inventories in Q4 FY25, tying up cash, primarily due to sales in the last two months and higher inventory built in anticipation of higher sales amidst pricing pressure. Management noted a reduction in Pen-G prices, impacting products like Cefepime, and is monitoring the market for stabilization. They aim to liquidate excess inventory over the next few months.

    07

    US Market Strategy and API Supply

    Historically, Orchid Pharma was dependent on a few customers for US market entry for its raw materials. To mitigate this, the company is now developing its own ANDAs and exploring partnerships with CMOs for US FDA-approved sites. While direct API supply to the US market is not anticipated in the next two years, development work is ongoing, and two customers are currently registering Orchid's API products.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.